An appraisal of antiretroviral drugs in hemodialysis

Kidney International

Volumn 60, Issue 3, 2001, Pages 821-830

  Izzedine, Hassane ^a   Launay Vacher, Vincent ^a   Baumelou, Alain ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AIDS; Dialysis; Dosing recommendations; End stage renal disease; HIV; Nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; GASTROINTESTINAL DISEASE; HEADACHE; HEMODIALYSIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; MOLECULAR WEIGHT; MYOPATHY; NAUSEA; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; RASH; REVIEW; URINARY EXCRETION; UROLITHIASIS; VERTIGO;

EID: 0035720558     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.060003821.x     Document Type: Article

References (47)

1. HIV-associated immune-mediated renal disease
2. Pattern of glomerular involvement in human immunodeficiency virus-infected patients: An Italian study
3. Dialysis
4. Drug dosage in patients during continuous renal replacement therapy
5. The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function
6. Endogenous accumulation products and serum protein binding in uremia
7. Alteration of plasma albumin in relation to decreased drug binding in uremia
8. Basic considerations
9. The biotransformation of drugs in renal failure
10. Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis
11. Pharmacokinetics in patients with renal failure
12. Drug dosage in dialysis patients
13. Heparin and human lipid metabolism
14. Drug therapy in patients undergoing haemodialysis: Clinical pharmacokinetical considerations
15. Nucleoside analogs: Similarities and differences
16. Zidovudine disposition in patients with renal impairment: Influence of hemodialysis
17. Influence of hemodialysis on zidovudine and its glucuronide (GAZT) pharmacokinetics: Two case reports
18. Didanosine pharmacokinetics in patients with normal and impaired renal function: Influence of hemodialysis
19. The effects of renal impairment on the pharmacokinetics of zalcitabine
20. Dosage adjustment of antiretroviral agents in patients with organ dysfunction
21. In vitro and in vivo disposition and metabolism of 3′-deoxy-2',3′-didehydrothymidine
22. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
23. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection
24. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of hemodialysis
25. Dosage of lamivudine in a haemodialysis patient
26. Abacavir
27. 1-infected patients with impaired renal function
28. Pharmacokinetics of nevirapine in haemodialysis
29. Pharmacokinetics of efavirenz in a patient on maintenance hemodialysis
30. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
31. Ritonavir
32. Pharmacokinetics of ritonavir and saquinavir in haemodialysis
33. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans
34. Indinavir pharmacokinetics in haemodialysis patients
35. Indinavir pharmacokinetics in haemodialysis dependent end stage renal failure
36. HIV-1 associated nephropathy and response to highly-active antiretroviral therapy
37. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency
38. 1-infected patients with renal dysfunction
39. Pharmacokinetics of zidovudine in end stage renal disease: Influence of hemodialysis
40. Zidovudine disposition during hemodialysis in a patient with acquired immunodeficiency syndrome
41. Pharmacokinetics of zidovudine in a patient on maintenance hemodialysis
42. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: Influence of hemodialysis and continuous ambulatory peritoneal dialysis
43. Antiviral therapy for HIV patients with renal insufficiency
44. Anti-HIV drugs
45. Management of antiretroviral therapy
46. Acute renal failure syndromes in human immunodeficiency virus infection